From: Evaluation of myosin VI, E-cadherin and beta-catenin immunostaining in renal cell carcinoma
 | Cytoplasmic beta-catenin | Nuclear beta-catenin | ||
---|---|---|---|---|
 | positive | negative | positive | negative |
Tumour class (T) | Â | Â | Â | Â |
1 (n = 71) | 5 (7%) | 66 (93%) | 36 (51%) | 35 (49%) |
2 (n = 11) | 2 (18%) | 9 (82%) | 2 (18%) | 9 (82%) |
3 (n = 59) | 6 (10%) | 53 (90%) | 24 (41%) | 35 (59%) |
4 (n = 6) | 0 (0%) | 6 (100%) | 3 (50%) | 3 (50%) |
Stage | Â | Â | Â | Â |
I (n = 66) | 5 (8%) | 61 (92%) | 34 (52%) | 32 (48%) |
II (n = 11) | 2 (18%) | 9 (82%) | 2 (18%) | 9 (82%) |
III (n = 51) | 5 (10%) | 46 (90%) | 21 (41%) | 30 (59%) |
IV (n = 19) | 1 (5%) | 18 (95%) | 8 (42%) | 11 (58%) |
Grade | Â | Â | Â | Â |
I (n = 5) | 0 (0%) | 5 (100%) | 2 (40%) | 3 (60%) |
II (n = 80) | 6 (7%) | 74 (93%) | 46 (58%) | 34 (42%) |
III (n = 38) | 2 (5%) | 36 (95%) | 9 (24%) | 29 (76%) |
IV (n = 22) | 4 (18%) | 18 (82%) | 8 (36%) | 14 (64%) |
Histological subtype of RCC | Â | Â | Â | Â |
clear cell (n = 130) | 10 (8%) | 120 (92%) | 58 (45%) | 72 (55%) |
papillary (n = 10) | 1 (10%) | 9 (90%) | 4 (40%) | 6 (60%) |
chromophobic (n = 5) | 1 (20%) | 4 (80%) | 3 (60%) | 2 (40%) |
undifferentiated (n = 2) | 1 (50%) | 1 (50%) | 0 (0%) | 2 (100%) |